News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Roquefort Therapeutics returns to the market with new study data

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Thomas Warner from Proactive after the biotech company announced that it had achieved 'significant results' in laboratory studies involving its anti-cancer mRNA treatment. Reginald reveals more information about the study and addresses the return of Roquefort shares to the market after a delayed audit prompted a temporary suspension. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 16, 2023 06:10 AM Eastern Daylight Time

Video
Article thumbnail News Release

Revolutionizing Pain Relief: The next generation of opioids | Interview with Ensysce Biosciences CEO

Ensysce Biosciences

Ensysce Bioscience CEO Dr Lynn Kirkpatrick joined Steve Darling from Proactive to share more details about the company that has proprietary technology platforms with the hopes of safer prescription drugs. The company does that through its Trypsin-Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. The key is the drug can only be activated or turned on when it is swallowed and comes into contact with the natural digestive enzyme trypsin, which is found in the small intestine. Kirkpatrick telling Proactive more about the platforms and also about its clinical trials which have shown promising results. Ensysce also plans to initiate a phase 3 trial and seek FDA approval. The company's goal is to address the opioid crisis by offering effective pain relief while minimizing the risk of addiction and abuse. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 15, 2023 01:34 PM Eastern Daylight Time

Video
Article thumbnail News Release

BioVie research and social impact initiatives recognize Alzheimer's & Brain Awareness Month

BioVie Inc

BioVie chief medical officer Dr Joseph Palumbo joins Natalie Stoberman from the Proactive newsroom to share the company's latest research and social impact on cognitive diseases to bring awareness to Alzheimer's & Brain Awareness Month. Palumbo says BioVie's latest research has shown improvements in motor behaviour for Parkinson's patients, reversing the "off state" experienced by some individuals. In addition, Palumbo explains there have also been observations of interesting effects on gene methylation and reversing stress-related changes in DNA. BioVie's research also focuses on the metabolic aspects of these diseases and their impact on cognition. The company has made social impact investments, including donations to organizations and partnering with universities for research initiatives. BioVie is dedicated to treating age-related diseases and expects to provide data from their studies by the end of the year. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

June 15, 2023 01:15 PM Eastern Daylight Time

Video
Article thumbnail News Release

Vivos Therapeutics highlights 1Q financial and operational growth with major acquisition

Vivos Therapeutics

Vivos Therapeutics chairman and CEO Kirk Huntsman joins Natalie Stoberman from the Proactive studios to discuss the company's first-quarter financial and operational highlights. Huntsman says the main highlight of comes from acquisition of certain US and international patents, product rights, and other miscellaneous intellectual property from Advanced Facialdontics to fill gaps in Vivos' product line. Huntsman also shares how the company's cost reduction efforts, distribution agreements, and the potential for further growth have been executed while the company continues to reach more patients and providers. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

June 15, 2023 12:55 PM Eastern Daylight Time

Video
Article thumbnail News Release

Valeo Pharma 2Q results showing 6th consecutive quarter of revenue growth

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has once again seen record numbers as it unveils its second-quarter financials. The numbers include the 6th consecutive quarter of revenue growth at $13.6 million, up 184% over 2Q 2022. Saviuk telling Proactive the number company also saw 6th consecutive quarter of adjusted EBITDA loss reduction at $1.7 million, which is a 53% improvement. Enerzair and Atectura continue to perform well with total prescriptions for the 12 months ending April 30, 2023 exceeding 45,000, up 654% over April 30, 2022. Looking ahead, the company projects revenues to exceed $60 million for the year, expecting continued growth in the third quarter. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 14, 2023 01:35 PM Eastern Daylight Time

Video
Article thumbnail News Release

SHARON PERSONAL CARE TO INTRODUCE ECO-FRIENDLY WET WIPE PRESERVATIVE AT WORLD OF WIPES 2023

Sharon Personal Care

Sharon Personal Care, a global supplier of innovative, environmentally friendly ingredient solutions for a broad range of personal care products, will introduce the SharoWIPES™ line, the newest addition to the company’s groundbreaking wet wipe preservative platform. This new preservative is a clean label and eco-friendly solution that is free from phenoxyethanol, parabens, CIT/MIT, and formaldehyde donors. It offers a technological breakthrough that protects both the formula and the nonwoven from the outside environment. While developing its SharoWIPES line, Sharon Personal Care researched the impact of the physical characteristics of different types of fabrics, ranging from traditional to trendy, on preservation. Through systematic analysis of factors, such as contact angle, pore size, fiber diameter, and zeta potential, they gained valuable insights into the physical contributions affecting preservation. The interaction between microorganisms and fabrics was also thoroughly examined to enhance comprehension and proactively address preservation difficulties. “Preservation of wet wipes is known to be a very challenging issue. The unique product characteristics of wipes introduce microbiological risks for both the formula and the fabric, and ingredient safety concerns are especially high with wet wipes, since they are used for baby care and on sensitive areas,” says Paul Salama, PhD, Chief Technical Officer and Head of Innovation at Sharon Personal Care. “Our SharoWIPES line was created following in-depth research to address these challenges. The solutions in this line are optimized with carefully selected hydrophilic components that are combined with a unique anti-biofilm mechanism to deliver an ultimate level of protection for the wipe and formula.” SharoWIPES feature a carefully selected combination of hydrophilic elements, complemented by an antibiofilm agent. This breakthrough formulation ensures high efficacy and broad-spectrum protection at minimal usage levels. SharoWIPES not only prevents the formation of biofilms, which can harbor bacteria, but also addresses the selective interaction between preservatives and fabrics. By delivering optimal protection for both the formula and the non-woven fabric. Key features and benefits of SharoWIPES™ include: Broad spectrum protection against bacteria Unique anti-biofilm mechanism to prevent bacterial adherence High efficacy at low-usage levels (<l%) Flexible platform suitable for various wet wipe applications Water-soluble and readily biodegradable Globally compliant Odorless and colorless The preservative components in SharoWIPES are readily biodegradable, making them environmentally friendly. The entire range is vegan, ensuring its suitability for use on baby wipes and sensitive areas. All components of SharoWIPES have also been clinically tested for safety and some have an E number due to their inclusion in food additives listings. To learn more about SharoWIPES preservative platform, meet us at World of Wipes International Conference, taking place July 17-20 at the Atlanta Marriott Marquis in Georgia. Dr. Noa Ziklo from Sharon’s Innovation Group will also deliver a presentation, A Holistic Approach Towards Wipes Preservation, at World of Wipes on Wednesday, July 19 at 12:00 noon, and will share findings from the research Sharon conducted to develop its line of wet wipe preservatives. For those not attending World of Wipes, more information about SharoWIPES and Sharon Personal Care's full range of products can be found at https://sharonpc.com. SharoWIPES: Sharon Personal Care will introduce its new SharoWIPES™ line, the newest addition to the company's groundbreaking wet wipe preservative platform, during World of Wipes 2023. About Sharon Personal Care Headquartered in Ashdod, Israel, Sharon Personal Care is a global supplier of innovative ingredient solutions for a broad range of personal care products – with specialized expertise in trending market segments. The company’s product portfolio includes unique preservatives, building blocks, and functional chemistries and active ingredients. Today’s Sharon has a proven track record of innovation combined with the ability to provide comprehensive solutions at light speed. With a solid foundation in environmentally sustainable chemistry, Sharon delivers multifunctional ingredient solutions that help differentiate personal care products in a fast-changing market. Established in 1977 by Dr. Danny Sommerfeld, the company employs more than 200 people worldwide, with manufacturing and scientific facilities on three continents. Sharon Personal Care is owned primarily by Tene Investment Funds (Tel Aviv), an Israeli private equity growth fund focused on the industrial and technology sectors. Contact Details Resource Advantage Dan Green dgreen@resourceadvantage.com Sharon Personal Care Laura Mills, Business Development Manager laura@sharonpc.com Company Website https://sharonpc.com/

June 14, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Negev Capital confident that big pharma will ultimately embrace psychedelics

Negev Capital

Negev Capital partner Ken Belotsky speaks to Thomas Warner from Proactive about the opportunities presented by the psychedelic startup scene. Belotsky describes the pharmaceutical market as "pretty conservative" overall, but says he believes that "soon we will see examples of M&A activity from big pharma into psychedelics, and as soon as it happens we will see a completely different [level of] interest from funds in the psychedelic space." The interview concludes with Belotsky discussing Negev Capital's sponsorship of the upcoming PSYCH symposium in London. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 14, 2023 03:56 AM Eastern Daylight Time

Video
Article thumbnail News Release

Ananda Developments says cannabinoid-based medicine will become "completely ubiquitous"

Ananda Developments Plc

Ananda Developments (AQSE:ANA) co-founder and CEO Melissa Sturgess visits the Proactive London studio to speak with Thomas Warner about the work the cannabinoid medicine development company is doing to help develop treatments for patients suffering from complex, chronic inflammatory pain conditions. Sturgess says that cannabinoid-based medicine will ultimately become "completely ubiquitous" and highlights the various fronts that Ananda is currently pushing forward on, including two upcoming phase II randomised controlled clinical trials. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 14, 2023 03:46 AM Eastern Daylight Time

Video
Article thumbnail News Release

Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update

Context Therapeutics

Context Therapeutics CEO Marty Lehr joins Natalie Stoberman from the Proactive studios to discuss the latest data on clinical cancer target Claudin 6 (CLDN6) presented at ASCO23 and how Context’s CTIM-76 CLDN6 X CD3 bispecific antibody sets itself apart from other CLDN6-targeted clinical candidates. Lehr says CLDN6 is differentially expressed on cancer cells with no or very low expression in normal, healthy adult tissue. CLDN6-enriched cancers include non-small cell lung (NSCLC), ovarian, testicular, and others. CTIM-76 is currently in preclinical development and is intended to direct activated immune T cells to CLDN6-expressing cancer cells. Preclinical studies of evaluating CTIM-76 demonstrates selective immune-mediated cell death of CLDN6-positive cancer cells. Contact Details Proactive Investors USA +1 347-449-0879 na-editorial@proactiveinvestors.com

June 13, 2023 01:34 PM Eastern Daylight Time

Video
1 ... 112113114115116 ... 301